Baseline characteristics
| CRP <150 mg/L | CRP ≥150 mg/L | Total overall (n=479) | |||||
| Lenzilumab (n=168) | Placebo (n=183) | CRP total (n=351) | Lenzilumab (n=53) | Placebo (n=46) | CRP total (n=99) | ||
| Gender | |||||||
| Male (%) | 106 (63) | 115 (63) | 221 (63) | 38 (72) | 35 (76) | 73 (74) | 311 (65) |
| Age | |||||||
| Mean (SD) | 60.9 (13.7) | 60.4 (14.3) | 60.6 (13.4) | 60.8 (13.7) | 61.1 (14.1) | 60.9 (13.7) | 61 (14) |
| BMI | |||||||
| Mean (SD) | 33.4 (8.8) | 32.5 (8.2) | 32.9 (8.5) | 32.5 (7.7) | 30.3 (6.2) | 31.5 (7.1) | 32.5 (8.2) |
| ≥30 Kg/m2 (%) | 58.3 | 57.4 | 57.8 | 56.6 | 41.3 | 49.5 | 55.1 |
| Race (%) | |||||||
| American Indian | 3 (2) | 0 (0) | 3 (1) | 1 (2) | 0 (0) | 1 (1) | 5 (1) |
| Asian | 6 (4) | 5 (3) | 11 (3) | 2 (4) | 0 (0) | 2 (2) | 14 (3) |
| Black | 25 (15) | 26 (14) | 51 (15) | 9 (17) | 6 (13) | 15 (15) | 72 (15) |
| White | 121 (72) | 134 (73) | 255 (73) | 38 (71.7) | 31 (67) | 69 (70) | 347 (72) |
| Multiple | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Other | 12 (7) | 18 (10) | 30 (9) | 3 (6) | 9 (20) | 12 (12) | 46 (9) |
| Ethnicity (%) | |||||||
| Hispanic or Latino | 48 (29) | 74 (40) | 122 (36) | 25 (47) | 21 (46) | 46 (47) | 185 (39) |
| Not Hispanic or Latino | 119 (71) | 108 (59) | 227 (65) | 27 (51) | 23 (50) | 50 (51) | 290 (60) |
| Supplemental oxygen (%) | |||||||
| Room air (Clinical ordinal score=5) | 13 (8) | 10 (6) | 23 (7) | 2 (4) | 2 (4) | 4 (4) | 41 (9) |
| Low-flow oxygen (Clinical ordinal score=4) | 90 (54) | 93 (51) | 183 (52) | 26 (49) | 23 (50) | 49 (50) | 242 (50) |
| High flow oxygen or NPPV (Clinical ordinal score=3) | 65 (39) | 80 (44) | 145 (41) | 25 (47) | 21 (46) | 46 (47) | 197 (41) |
| CRP (mg/L) | |||||||
| Mean (SD) | 62.8 (39.8) | 67.1 (38.4) | 65.1 (39.1) | 219 (56.6) | 210 (53.4) | 215 (55.0) | 98.0 (76.0) |
| Median | 58.8 | 64.0 | 61.1 | 204 | 200 | 201 | 79.0 |
| IQR | (27.7–92.0) | (34.9–98.7) | (32.2–96.8) | (185-238) | (168-226) | (175-232) | (41.0–137.1) |
| Concomitant medications (%) | |||||||
| Corticosteroids only | 31 (18) | 44 (24) | 75 (21) | 17 (32) | 8 (18) | 25 (26) | 118 (25) |
| Remdesivir only | 5 (3) | 6 (3) | 11 (3) | 1 (2) | 2 (4) | 3 (1) | 16 (3) |
| Corticosteroids and remdesivir | 127 (75) | 132 (71) | 259 (73) | 33 (62) | 33 (73) | 66 (67) | 331 (69) |
| Co-morbidity (%) | |||||||
| Hypertension | 106 (63) | 131 (72) | 237 (68) | 26 (49) | 25 (54) | 51 (52) | 314 (66) |
| Congestive heart failure | 24 (14) | 15 (8) | 39 (11) | 7 (13) | 7 (15) | 14 (14) | 55 (12) |
| Coronary artery disease | 24 (14) | 23 (13) | 47 (13) | 10 (19) | 6 (13) | 16 (16) | 64 (14) |
| Diabetes | 86 (51) | 103 (56) | 189 (54) | 26 (49) | 24 (52) | 50 (51) | 158 (53) |
| Chronic liver disease | 8 (5) | 11 (6) | 19 (5) | 2 (4) | 3 (7) | 5 (5) | 17 (5) |
| Chronic kidney disease | 26 (16) | 25 (14) | 51 (15) | 8 (15) | 6 (13) | 14 (14) | 67 (14) |
| Asthma | 23 (14) | 10 (6) | 33 (9) | 9 (17) | 6 (13) | 15 (15) | 52 (11) |
| Interstitial lung disease | 3 (2) | 0 (0) | 3 (1) | – | 1 (2) | 1 (1.0) | 2 (0) |
| COPD | 14 (8) | 15 (8) | 29 (8) | 4 (7.5) | 1 (2) | 5 (5) | 36 (7) |
BMI, body mass index; CRP, C reactive protein.